Mesenchymal-epithelial transition factor (MET) is an important tumor driver gene in non-small cell lung cancer (NSCLC). In recent years, targeted therapy for MET signaling pathway has become a new target for lung cancer treatment. As the world's first oral, highly selective and potent MET inhibitor, tepotinib has been approved by Japan and the United States FDA for the treatment of advanced or recurrent NSCLC patients with unresectable and MET exon 14 skipping mutations. At the same time, it has shown good safety and efficacy in clinical studies. This article mainly reviewed the current clinical studies of tepotinib in NSCLC, liver cancer, NSCLC with brain metastasis and so on.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |